(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Grass Care Administrations for a Wonderful, Sound Yard - 2Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- 3Revealing the Incomparable Realms: An Excursion through Power and Inheritance
- 4CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year
- 5German Cabinet advances bill to cut greenhouse emissions from fuels
- Green Inflections: A Manual for Inside Plants
- In blow to Lula, Brazil Congress revives controversial environmental bill
- Kremlin: Russian troops conquer Pokrovsk after year of intense combat
- 5 Bike Brands for Ordinary Use
- Vote In favor of Your Favored Pet Consideration Administration
- 4 Sound blocking Earphones for Prevalent Sound and Solace
- Figure out How to Amplify the Resale Worth of Your Kona SUV
- 5 Critical Rules For Business Regulation Chiefs
- The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree
